SARC-CTOS imaging symposium: Introduction to the problem from a clinical perspective

Oncologist

Volumn 13, Issue SUPPL. 2, 2008, Pages 1-3

  Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Imaging; Response; Sarcoma

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE COURSE; HUMAN; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EDITORIAL; METHODOLOGY; SARCOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; RESEARCH DESIGN; SARCOMA; TREATMENT OUTCOME;

EID: 47749105734     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-s2-1     Document Type: Conference Paper

References (12)

1. Freireich EJ, Gehan EA, Sulman Det al. The effect of chemotherapy on acute leukemia in the hum an. J Chronic DLS 1961;14:593-608.
2. Benjamin RS, Choi H, Macapinlae HA et al. We should desist using RECIST, at least in GIST. JClinOncol2007;25:1760-1764.
3. Karnofsky DA. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 1961;2:709-712.
4. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
5. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst 2000;92:205-216.
6. Jaffe CC. Response assessment in clinicaltrials: Implications for sarcoma clinical trial design. The Oncologist 2008:13(supp12):14-18.
7. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Publication No. 48. Geneva, Switzerland: World Health Organization, 1979.
8. Park JO, Lee SI, Song SY et al. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria, Jpn J Clin Oncol 2003;33:533-537.
9. Bona donna G, Monfardini S, De Lena M et al. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970;30:2572-2582.
10. Jaffe N, Recent advances in the chemotherapy of metastatic osteogenie sarcoma. Cancer 1972;30:1627-1631.
11. Bonadonna G, Beretta G, Taneini Get al. [Adriamycin as a single agent in various forms of advanced neoplasia of adults and children (author's transl).] Tumori 1974;60:373-391. Italian.
12. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976;38:3 88-394.